1. Home
  2. IBRX vs VSAT Comparison

IBRX vs VSAT Comparison

Compare IBRX & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$7.63

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Logo ViaSat Inc.

VSAT

ViaSat Inc.

HOLD

Current Price

$74.67

Market Cap

9.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBRX
VSAT
Founded
2014
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
9.6B
IPO Year
2015
1996

Fundamental Metrics

Financial Performance
Metric
IBRX
VSAT
Price
$7.63
$74.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
6
Target Price
$12.57
$59.80
AVG Volume (30 Days)
8.5M
2.0M
Earning Date
05-08-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
38.71
94.42
EPS
N/A
N/A
Revenue
$113,288,000.00
N/A
Revenue This Year
$88.59
$5.32
Revenue Next Year
$131.15
$3.57
P/E Ratio
N/A
N/A
Revenue Growth
668.31
N/A
52 Week Low
$1.95
$26.10
52 Week High
$12.43
$93.03

Technical Indicators

Market Signals
Indicator
IBRX
VSAT
Relative Strength Index (RSI) 49.70 46.07
Support Level $6.68 $67.49
Resistance Level $8.46 $75.57
Average True Range (ATR) 0.33 5.06
MACD 0.06 -1.21
Stochastic Oscillator 58.28 15.27

Price Performance

Historical Comparison
IBRX
VSAT

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

About VSAT ViaSat Inc.

Viasat Inc an world-wide provider of communications technologies and services, focused on making connectivity accessible, available and secure for current and future customers world-wide. The company has two reportable segments: communication services and defense and advanced technologies. It generates majority of revenue from communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers. It has presence in United States and Outside United States. The company generates majority of revenue from United States. Its products are Antennas, Terminals & radios, Modems, Semiconductors, Cybersecurity, Software & services, Home internet.

Share on Social Networks: